2-[2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzimidazol-5-yl]-4,5-dihydro-1,3-oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzimidazol-5-yl]-4,5-dihydro-1,3-oxazole
• 化学式: C₁₉H₂₀N₄O₃S
• 分子量: 384.5
• InChiKey: OFPUAQDJLPMNKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
  申请人：AstraZeneca AB

  公开号：EP2275139A1

  公开（公告）日：2011-01-19

  An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of a capsule dosage form. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

  一种口服药物剂型，包含一种易受酸影响的质子泵抑制剂和一种或多种非甾体抗炎药的固定制剂，其中质子泵抑制剂由肠溶包衣层保护。固定制剂为胶囊剂型。新的固定制剂尤其适用于治疗与非甾类抗炎药治疗相关的胃肠道副作用。
• Solid composition comprising a proton pump inhibitor
  申请人：Blychert Eva

  公开号：US20070053981A1

  公开（公告）日：2007-03-08

  The present invention related to a method for oral administration of a solid composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or more pharmaceutically acceptable thickeners capable of forming a viscous medium when dispersed in an aqueous carrier. Alternatively, the enteric coated pellets are in admixture with a viscous medium. The formed aqueous viscous suspension is administered through a gastric tube. The method and composition are especially aimed for treatment of patients in need of a proton pump inhibitor and having difficulties to swallow or for pediatric patients.
• Modified Release Tablet Formulations for Proton Pump Inhibitors
  申请人：Clemmensen Niclas

  公开号：US20080003281A1

  公开（公告）日：2008-01-03

  An oral solid pharmaceutical dosage form comprising an acid sensitive proton pump inhibitor (PPI) as single active drug, releasing the PPI in two separate pulses, one immediate and one delayed. The PPI is formulated into a core material in the form of tablets, which are coated i.a. with a combination of a delay release modifying layer and a lag time controlling layer that together achieves beneficial release properties. The tablets are further provided with an enteric coating layer. The application also relates to processes for preparing the dosage forms as well as their use in the treatment of gastrointestinal diseases.
• Administration of pharmaceuticals
  申请人：Cederberg Christer

  公开号：US20070276007A1

  公开（公告）日：2007-11-29

  A new administration regimen giving an extended plasma concentration profile of a H + , K + -ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H + , K + -ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be administered once daily.
• Solid Dosage Form Comprising Proton Pump Inhibitor and Suspension Made Thereof
  申请人：Persson Eva

  公开号：US20080020053A1

  公开（公告）日：2008-01-24

  A solid rapidly gelling oral pharmaceutical dosage form, as well as aqueous suspensions prepared thereof, comprising an acid sensitive proton pump inhibitor as active ingredient distributed in a multitude of enteric coated pellets and a suspension modifying granulate comprising a rapidly dissolving diluent granulated together with a gelling agent chosen among xanthan gums, and an acidic pH-regulating agent and a binder. The suspension modifying granulate is rapidly disintegrating and gelling when suspended in an aqueous medium and thus forming a homogenous stable and robust suspension having a reproducible and stable viscosity. Furthermore the invention relates to an improved process for its manufacture and the use of such formulation in medical treatment including prevention of gastrointestinal disorders in humans.